What is Anika Therapeutics's D&A?

Anika Therapeutics (ANIK) reported D&A of $1.51M in Q2 2026.

How has Anika Therapeutics's D&A changed year-over-year?

Anika Therapeutics's D&A increased by 17.6% year-over-year, from $1.28M to $1.51M.

What is the long-term trend for Anika Therapeutics's D&A?

Over 4 years (2021 to 2025), Anika Therapeutics's D&A has grown at a -4.6% compound annual growth rate (CAGR), from $6.48M to $5.37M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Anika Therapeutics ANIK D&A

D&A at other companies

Zimmer Biomet HoldingsZBH

$162.1M+7.4%

Pacira BioSciences, Inc.PCRX

$14.32M0.0%

BioventusBVS

$1.11M-30.5%

Xtant Medical HoldingsXTNT

$534K-50.3%

Globus MedicalGMED

$29.53M-55.3%

AVN

AVNSAVNS

$10.2M+6.3%

Other financials

Income statement

See full

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Balance sheet

See full

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Cash flow

See full

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Valuation

See full

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Profitability

See full

Net margin-3.4%-1.6pp

FCF margin0.5%—

Returns & leverage

See full

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anika Therapeutics's D&A?: Anika Therapeutics (ANIK) reported D&A of $1.51M in Q2 2026.
How has Anika Therapeutics's D&A changed year-over-year?: Anika Therapeutics's D&A increased by 17.6% year-over-year, from $1.28M to $1.51M.
What is the long-term trend for Anika Therapeutics's D&A?: Over 4 years (2021 to 2025), Anika Therapeutics's D&A has grown at a -4.6% compound annual growth rate (CAGR), from $6.48M to $5.37M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.